ADHAM MALATY: Open Payments
NPI 1174818587 · SANTA BARBARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$829 in 39 payments from 8 companies in 2025. Trend: 2023 $379 · 2024 $491 · 2025 $829
Food & beverage: $789Education: $40
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 12 | $191 |
| ABBVIE INC. | 9 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $156 |
| E.R. Squibb & Sons, L.L.C. | 5 | $117 |
| Tris Pharma Inc | 3 | $74 |
| Alkermes, Inc. | 2 | $55 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: VRAYLAR, FANAPT, CAPLYTA, COBENFY, Dyanavel XR, ARISTADA, HETLIOZ, SPRAVATO.
Industry payments across CA — which companies pay providers there.
